Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the drug levels, effectiveness, and safety of Deucravacitinib in children and adolescents aged 4 to under 18 years who have moderate to severe plaque psoriasis. The study includes two age groups Cohort 1 for ages 12 to under 18 years, and Cohort 2 for ages 4 to under 12 years. It is a randomized, double-blind, placebo-controlled Phase 3 trial sponsored by Bristol-Myers Squibb. Participants in each cohort enter two parts of the study. Part A assesses drug levels to select two dose levels for further study in Part B, which evaluates the efficacy and safety of these doses. Following Parts A and B, a long-term extension lasting up to five years observes the long-term safety and tolerability of Deucravacitinib in those who completed earlier parts. During the study, participants undergo assessments including monitoring drug plasma concentrations at weeks 2 and 16, psoriasis severity improvements measured by PASI and sPGA scores at week 16, and safety evaluations of adverse events and growth parameters up to 316 weeks. Laboratory tests and physical exams occur up to week 52. This comprehensive monitoring helps researchers understand how the drug works and its impact on growth and health over time.